In this session, global experts will discuss the use of fibrinogen concentrate, prothrombin complex concentrates (PCCs) and FXIII Concentrate for the treatment of acquired deficiencies during uncontrolled bleeding. Speakers will discuss the risk and benefits, alternatives, and optimal laboratory assessments of each of the products. The speakers will highlight and critically assess the evidence provided from randomized clinical trials and observational studies to support the use of the products. The risk of thrombotic events will also be discussed and compared to standard blood components. Dr. Jeannie Callum, a Canadian transfusion medicine expert and experienced researcher involved in multiple fibrinogen concentrate randomized controlled trials, will discuss the use of fibrinogen concentrate. Dr. Oliver Grottke, a German expert on the use of PCCs in the surgical setting, will discuss PCCs. Dr. Thorsten Haas, a Swiss researcher and anesthesiologist, will discuss the use of FXIII concentrate in the setting of acquired FXIII deficiency.
At the completion of this session, participants should be able to:
Analyze the evidence available to support the use of PCCs, fibrinogen concentrate and FXIII in the treatment of non-hemophilia patients
Recognize the risks and benefits of PCCs, fibrinogen concentrate and FXIII
Propose settings for the optimal use of PCCs, fibrinogen concentrate and FXIII
Transfusion Medicine Specialist and Hematologist,
Sunnybrook Health Sciences Centre
Weill Cornell Medicine Department of Pathology and Laboratory Medicine